{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:30:35Z","timestamp":1793788235840,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["KWF 10913\/2017-1"],"award-info":[{"award-number":["KWF 10913\/2017-1"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["754688"],"award-info":[{"award-number":["754688"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biopha.2024.116362","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T06:35:17Z","timestamp":1709361317000},"page":"116362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo"],"prefix":"10.1016","volume":"173","author":[{"given":"Gerke","family":"Ariaans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiske F.","family":"Tiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardus","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Gerding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn J.H.","family":"Waaijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco A.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk-Jan","family":"Reijngoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116362_bib1","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116362_bib2","unstructured":"Triple-Negative Breast Cancer 2021. \u3008https:\/\/www.breastcancer.org\/types\/triple-negative\u3009 (accessed July 3, 2021)."},{"key":"10.1016\/j.biopha.2024.116362_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116362_bib4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor\u2013expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116362_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116362_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116362_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600573","article-title":"Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects","volume":"10","author":"Thomas","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116362_bib8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2024.116362_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116362_bib10","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"Jovanovi\u0107","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116362_bib11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.7150\/jca.24035","article-title":"Phase I\/II clinical trial of everolimus combined with gemcitabine\/cisplatin for metastatic triple-negative breast cancer","volume":"9","author":"Park","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2024.116362_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3634","article-title":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","volume":"16","author":"Singh","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2024.116362_bib13","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116362_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116362_bib15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12885-017-3230-8","article-title":"Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells","volume":"17","author":"Ariaans","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.116362_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ab.2003.07.008","article-title":"Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots","volume":"322","author":"van Dijk","year":"2003","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2024.116362_bib17","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1158\/1078-0432.CCR-12-0406","article-title":"Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model","volume":"18","author":"van der Bilt","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116362_bib18","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1535-7163.MCT-11-0497","article-title":"Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models","volume":"10","author":"Cheong","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116362_bib19","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1021\/acs.analchem.1c01040","article-title":"Simultaneous quantification of the concentration and carbon isotopologue distribution of polar metabolites in a single analysis by gas chromatography and mass spectrometry","volume":"93","author":"Evers","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2024.116362_bib20","unstructured":"Percie du Sert N., Hurst V., Ahluwalia A., Alam S., Avey M.T., Baker M., et al. The ARRIVE Guidelines 2.0: updated guidelines for reporting animal research. n.d."},{"key":"10.1016\/j.biopha.2024.116362_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/FTD.0b013e318192304c","article-title":"Robust, high-throughput LC-MS\/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood","volume":"31","author":"Koster","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2024.116362_bib22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.ekir.2020.06.009","article-title":"Renal trapping in accidental metformin intoxication","volume":"5","author":"Posma","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.biopha.2024.116362_bib23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can. J. Biochem Physiol."},{"key":"10.1016\/j.biopha.2024.116362_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2337\/dc09-1284","article-title":"Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations","volume":"33","author":"Frid","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116362_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110971","article-title":"The impact of Sample Handling Time on metformin serum concentration","volume":"133","author":"Sutkowska","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116362_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185092","article-title":"Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition","volume":"12","author":"Lampa","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116362_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","article-title":"Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship","volume":"121","author":"Deppenweiler","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2024.116362_bib28","article-title":"Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients","author":"Phillips","year":"2022","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2024.116362_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1476-4598-7-79","article-title":"Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes","volume":"7","author":"Fan","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116362_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129848","article-title":"Pyruvate carboxylase is up-regulated in breast cancer and essential to support growth and invasion of MDA-MB-231 cells","volume":"10","author":"Phannasil","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.116362_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01373","article-title":"mTORC1 as a regulator of mitochondrial functions and a therapeutic target in cancer","volume":"9","author":"de la Cruz L\u00f3pez","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2024.116362_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-022-00287-8","article-title":"13C tracer analysis suggests extensive recycling of endogenous CO2 in vivo","volume":"10","author":"Duan","year":"2022","journal-title":"Cancer Metab."},{"key":"10.1016\/j.biopha.2024.116362_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201903483","article-title":"Targeting pyruvate carboxylase by a small molecule suppresses breast cancer progression","volume":"7","author":"Lin","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2024.116362_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1940-6207.CAPR-16-0211-T","article-title":"Metformin accumulation correlates with organic cation transporter 2 protein expression and predicts mammary tumor regression in vivo","volume":"10","author":"Checkley","year":"2017","journal-title":"Cancer Prev. Res (Philos. )"},{"key":"10.1016\/j.biopha.2024.116362_bib35","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/0008-5472.CAN-13-0080","article-title":"Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism","volume":"73","author":"Fendt","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116362_bib36","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/cncr.28853","article-title":"Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial","volume":"120","author":"Mitsuhashi","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2024.116362_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cmet.2016.03.006","article-title":"Metformin pharmacokinetics in mouse tumors: implications for human therapy","volume":"23","author":"Dowling","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.116362_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature24057","article-title":"Glucose feeds the TCA cycle via circulating lactate","volume":"551","author":"Hui","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2024.116362_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.devcel.2020.06.018","article-title":"Cancer cells don\u2019t live alone: metabolic communication within tumor microenvironments","volume":"54","author":"Li","year":"2020","journal-title":"Dev. Cell"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224002464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:16:18Z","timestamp":1793787378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"alternative-id":["S0753332224002464"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116362","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116362"}}